D-0049-2015 Class III Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0049-2015 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Oct 21, 2014 and is designated Class III. Reason for recall: Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for… The recall status is terminated (terminated Apr 3, 2017). Affected quantity: 1,966 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 5, 2014
Initiation Date
Oct 21, 2014
Termination Date
Apr 3, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,966 bottles

Product description

Carbamazepine Tablets USP, 200 mg, 1000 Tablets per Bottle, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 26110 Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4005-3.

Reason for recall

Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.

Distribution pattern

IL, OH, LA

Code information

Lot 137393, exp. 10/2016

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0049-2015
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0049-2015. Report a data issue: hello@regdatalab.com.